Therapy in allergic rhinoconjunctivitis: new horizons.
Allergic Rhinitis (AR) is a common disease that impacts productivity and has significant patient morbidity. We have a variety of agents available for the treatment of AR, but numerous patients still lack good control of symptoms and some are tolerating undesired side effects. Surveys have shown 1/5 of patients with AR are not fully satisfied with their AR medications and almost 1/2 feel they receive insufficient attention from their physicians. Newer agents for the treatment of AR are in development, and an overview of some of these are presented here.
Mahr
Todd A
TA
Department of Allergy/Immunology, Gundersen Lutheran Medical Center, University of Wisconsin School of Medicine and Public Health, La Crosse, Wisconsin 54601, USA. tamahr@gundluth.org
D018926:Anti-Allergic Agents / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000628:therapy
D018926:Anti-Allergic Agents